Loading
Adding a year of immunotherapy to chemotherapy after surgery halved recurrences in stage III colon cancers with a broken DNA spell-checker.
ASCO 2025 plenary: 3-year DFS 86.4% vs 76.6% (HR 0.50). The first phase 3 to show immunotherapy benefit in the adjuvant colon setting; establishes a new standard for the ~10-15% of stage III colon cancers that are dMMR. Whether chemotherapy is needed at all in this group (NICHE-2 logic) is the next question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
712 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Disease-free survival at 3 yearsprimary | FOLFOX + atezolizumab | 355 | 86.4 percent | 0.5 (0.34 to 0.72) | - | link |
| FOLFOX | 357 | 76.6 percent |
Shares Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer, Neoadjuvant checkpoint inhibitor → surgery (or no surgery) in dMMR colorectal cancer, Mismatch-repair deficient (MSI-high) colorectal cancer, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
Shares Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer, Neoadjuvant checkpoint inhibitor → surgery (or no surgery) in dMMR colorectal cancer, Mismatch-repair deficient (MSI-high) colorectal cancer, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
Shares IDEA collaboration, Neoadjuvant / adjuvant / perioperative, FOLFOX (5-FU, leucovorin, oxaliplatin), Colon cancer (adenocarcinoma of the colon).
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Neoadjuvant / adjuvant / perioperative, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, FOLFOX (5-FU, leucovorin, oxaliplatin).
Shares Alliance N0147, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Neoadjuvant / adjuvant / perioperative, Colon cancer (adenocarcinoma of the colon).
Shares IDEA collaboration, Neoadjuvant / adjuvant / perioperative, FOLFOX (5-FU, leucovorin, oxaliplatin), Colon cancer (adenocarcinoma of the colon).
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Atezolizumab, FOLFOX (5-FU, leucovorin, oxaliplatin), Colon cancer (adenocarcinoma of the colon).
Shares IDEA collaboration, Neoadjuvant / adjuvant / perioperative, FOLFOX (5-FU, leucovorin, oxaliplatin), Colon cancer (adenocarcinoma of the colon).